



CORPORATE PROFILE

Headquartered in Mumbai, Indoco is a fully integrated, research-oriented pharmaceutical company with a presence in 55 countries. The Company's turnover is US\$ 212 million, with a human capital of 6000 employees, including over 400 skilled scientists and Field Staff, who are the strength of the organization.

The Company has 11 manufacturing facilities, 7 for Finished dosages and 4 for APIs, supported by a state-of-the-art R&D facility in Navi Mumbai and a Clinical Research Organization in Hyderabad. The facilities have been approved by most global Regulatory Authorities, including USFDA and UK-MHRA.

Indoco develops and manufactures a wide range of pharmaceutical products for the Indian and international markets. Indoco generates more than 106 million prescriptions annually from over 2,30,000 doctors belonging to various specialties.

The Company's R&D team develops non-infringing processes for APIs, formulations and various dosage forms like Immediate Release Tablets, Capsules, Multi-Unit Pellet Systems (MUPS), Pulsatile Drug Delivery Systems, Sterile Ophthalmic Ointments, Ophthalmic Gels, Suspensions and Solutions, Extended Release Tablets with matrix technology, complex ophthalmic products like emulsions and nano suspensions, as well as a range of injectable solutions, suspensions and depot based long-acting injectables.

Indoco has 9 domestic marketing divisions with a strong brand portfolio in various therapeutic segments, including Stomatologicals, Gastro-Intestinal, Respiratory, Anti-Infectives, Vitamins/Minerals/Nutrients, Cold & Cough, Ophthalmics, Antifungal, Antidiabetic & Cardiovascular, Urology, and several others. Top Indoco brands include Cyclopam, Febrex Plus, Sensodent-K, Karvol Plus, ATM, Oxipod, Cital, Cital UTI, Sensoform, Sensodent-KF, Cloben-G, Tuspel Plus, Dropizin, Tuspel LS, Glychek, Kidodent, Carmicide, Rexidin, MCBM 69, Methycal, Cal-Aid, Macuchek, Mofloren, Irivisc, PGVISC, Nepachek, Noxa, Subital, Aloja, Glychek, etc.

Indoco exports a variety of products to regulated and emerging markets, including the USA and EU. The Company has tie-ups with large generic companies and works in close coordination with its customers to leverage its core competencies. Indoco's branded formulations are promoted and distributed across India and in Emerging Markets of South East Asia, Africa, Latin America

and CIS countries. With several legacy brands in India and a fast-growing ethical business in emerging markets, Indoco is a partner-of-choice for several large pharmaceutical companies across the globe.

On the manufacturing front, Indoco's core strength lies in the development of complex sterile formulations. Indoco has several first to file ANDAs and a strong development pipeline to support the Company's growth. The Company's focus is to develop differentiated generics and innovative specialty products to strengthen its global specialty pipeline, a key determinant of future growth. Research and development is crucial for the pharma industry to be able to offer better products to fulfill the unmet needs of patients. Indoco has a state-of-the-art R&D centre in Navi Mumbai that spans over 100,000 square feet and is dedicated to the future of modern medicine.

Recently, Indoco acquired 85% of the equity stake in the US based FPP Holding Company, LLC ("FPP Holding") for USD 4 Million from Contract Pharmacal Corp. ("CPC").

FPP Holding is the holding company of Florida Pharmaceutical Products, LLC ("FPP") which is based in Florida and engaged in marketing and distribution of generic pharmaceutical products in the USA. This strategic investment marks a significant milestone for the Company, solidifying its position as a key player in the US market. The smart synergy between Indoco and FPP will enable the Company to commercialize its registered generic products with a direct presence in the USA.

The Indoco Analytical Solutions (IAS) division is USFDA approved and based at Rabale, Navi Mumbai. The division serves customers for their analytical research needs, utilizing state-of-the-art instruments and infrastructure through a team of experts in the field. The XIDEL division offers end-to-end engineering and consulting services for all phases of project development, right from project design to validation. XIDEL has been providing these services to the pharmaceutical and API sectors for the past 15 years and has completed several projects.

AnaCipher CRO, based in Hyderabad, is a USFDA inspected clinical research facility and is spread over 40,000 sq. ft area with 146 beds and staffed by experienced professionals providing clinical trial solutions, including bioavailability and bioequivalence (BA/BE)/Phase I/Phase II studies for pharmaceutical companies globally. The CRO has successfully completed more than 500 studies in multiple therapeutic areas such as, cardiovascular, diabetes, oncology, anti-retrovirals and antacids.

The Company works actively towards the betterment of society and helps the underprivileged across India and overseas through its CSR initiative "SUMATI SANGOPAN" in the areas of health, education, sanitation and environment. It was the philosophy of the Founder, Late Shri. Govind

Ramnath Kare to give back to society in proportion to what one receives from it. This philosophy has always been at the forefront of CSR initiatives at Indoco. Indoco reaches out to the needy with a significant focus on the welfare of women, the aged and children, thereby creating better lives for a brighter future. ESG (Environmental, Social and Governance) is a framework to map out a company's impact on the World. The Company's core corporate responsibility is to practice its corporate values through a commitment to grow in a socially and environmentally responsible way, while meeting the interests of its stakeholders.

We are healing lives with passion, commitment and perseverance.